Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748059 | 0.91 | — | — | |
| SCHEMBL23748074 | 0.82 | POLB (0.30) | POLB | |
| SCHEMBL30080527 | 0.80 | — | — | |
| SCHEMBL17695958 | 0.79 | POLB (0.33) | POLB | |
| SCHEMBL30436972 | 0.78 | POLB (0.31) | POLB | |
| SCHEMBL25209584 | 0.78 | POLB (0.31) | POLB | |
| SCHEMBL23748081 | 0.78 | PTGS2 (0.36) | POLB | |
| Hydrochloric Acid SCHEMBL30080420 | 0.78 | — | — | |
| SCHEMBL23971611 | 0.78 | POLB (0.34) | POLB | |
| SCHEMBL30177583 | 0.78 | POLB (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3864015-B1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATEIVES | BAYER AG (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-3864015-B1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATEIVES | BAYER AG (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-112867713-B | Process for preparing imidazole derivatives | 拜耳公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11479565-B2 | Process for preparing substituted imidazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| EP-3864016-B1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES | BAYER AG (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220009930-A1 | PROCESS FOR PREPARING IMIDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20210380611-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-09 | — | — | US | disclosed |
| EP-3864015-A1 | PROCESS FOR PREPARING IMIDAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3864016-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3636645-A1 | PROCESS FOR THE PREPARATION OF SULFUR-SUBSTITUTED PYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479565-B2 | Process for preparing substituted imidazole derivatives | CYP4B1, MAOB, CYP3A4 | POLB 56/4885 |
| US-20210380611-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES | CYP4B1, MAOB, CYP3A4 | POLB 56/4885 |
| US-20220009930-A1 | PROCESS FOR PREPARING IMIDAZOLE DERIVATIVES | UQCRB, CYP3A4, H1-4 | POLB 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.